biotech news today obesity drugs glp-1 ADA '26: Lilly's dominance, Pfizer's 'foundational' drug and Roche's 'me-too' option GLP-1 Therapies Reshape Future of

This 12-week study aimed to investigate the effects of dietary allulose supplementation in a rat model of diet-induced obesity and T2D

This fasting period is meant to minimise the risk of aspiration of gastric contents, a potentially serious complication where gastric contents can enter the lungs during the procedure

Updated July 2026 The Ozempic and GLP-1 gastroparesis lawsuits involve claims that manufacturers of GLP-1 medications such as Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity, Zepbound, and Saxenda failed to adequately warn patients and doctors about the potential risk of developing gastroparesis (i.e., stomach paralysis or delayed gastric emptying), a serious gastrointestinal injury that can cause persistent nausea, vomiting, abdominal pain, bloating, dehydration, malnutrition, hospitalization, or the need for feeding tubes or other invasive treatment

Does the Medication of Each Group Make a Difference or Is There a Class Effect

The team didn't stop there, either